QAMZOVA

Launch

meloxicam

NDAINTRAVENOUSSOLUTION
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Clinical Trials (5)

NCT03684265Phase 1Completed

A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets

Started Oct 2018
26 enrolled
Healthy
NCT01750931N/ACompleted

This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.

Started Sep 2013
28 enrolled
Arthritis, Rheumatoid
NCT01430559N/ACompleted

Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

Started Oct 2011
408 enrolled
Osteoarthritis of the Knee
NCT02183181Phase 1Completed

Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers

Started Nov 2008
6 enrolled
Healthy
NCT00239382Phase 3Completed

A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis

Started Jul 2004
150 enrolled
Arthritis, Rheumatoid

Loss of Exclusivity

LOE Date
Jul 19, 2040
175 months away
Patent Expiry
Jul 19, 2040

Patent Records (1)

Patent #ExpiryTypeUse Code
12059423
Jul 19, 2040
SubstanceProduct